Mesenchymal Stem Cell Group, University of Adelaide, Adelaide SA 5000, Australia.
Stem Cells Dev. 2009 Nov;18(9):1253-62. doi: 10.1089/scd.2008.0400.
Mesenchymal stromal cells (MSCs) and their precursor cells (MPCs) can proliferate and differentiate into multiple mesodermal and some ectodermal and endodermal tissues. Culture-expanded MSCs are currently being evaluated as a possible cell therapy to replace/repair injured or diseased tissues. While a number of mAb reagents with specificity to human MSCs, including STRO-1, STRO-3 (BLK ALP), CD71 (SH2, SH3), CD106 (VCAM-1), CD166, and CD271, have facilitated the isolation of purified populations of human MSCs from primary tissues, few if any mAb reagents have been described that can be used to isolate equivalent cells from other species. This is of particular relevance when assessing the tissue regenerative efficacy of MSCs in large immunocompetent, preclinical animal models of disease. In light of this, we sought to generate novel monoclonal antibodies (mAb) with specific reactivity against a cell surface molecule that is expressed at high levels by MSCs from different species. Using CD106 (VCAM-1)-selected ovine MSCs as an immunogen, mAb-producing hybridomas were selected for their reactivity to both human and ovine MSCs. One such hybridoma, termed STRO-4, produced an IgG mAb that reacted with <5% of human and ovine bone marrow (BM) mononuclear cells. As a single selection reagent, STRO-4 mAb was able to enrich colony-forming fibroblasts (CFU-F) in both human and ovine BM by 16- and 8-folds, respectively. Cells isolated with STRO-4 exhibited reactivity with markers commonly associated with MSCs isolated by plastic adherence including CD29, CD44, and CD166. Moreover, when placed in inductive culture conditions in vitro, STRO-4(+) MSCs exhibited multilineage differentiation potential and were capable of forming a mineralized matrix, lipid-filled adipocytes, and chondrocytes capable of forming a glycosaminoglycan-rich matrix. Biochemical analysis revealed that STRO-4 identified the beta isoform of heat shock protein-90 (Hsp90beta). In addition to identifying an antibody reagent that identifies a highly conserved epitope expressed by MSCs from different species, our study also points to a potential role for Hsp90beta in MSC biology.
间充质基质细胞 (MSCs) 和它们的前体细胞 (MPCs) 可以增殖并分化为多种中胚层以及一些外胚层和内胚层组织。目前,培养扩增的 MSCs 正在被评估为一种可能的细胞疗法,以替代/修复受损或患病的组织。虽然有许多针对人类 MSCs 的单克隆抗体 (mAb) 试剂,包括 STRO-1、STRO-3 (BLK ALP)、CD71 (SH2、SH3)、CD106 (VCAM-1)、CD166 和 CD271,这些试剂促进了从原代组织中分离纯化的人类 MSCs 群体,但很少有 mAb 试剂能够用于从其他物种中分离等效细胞。当评估 MSCs 在大型免疫活性、疾病的临床前动物模型中的组织再生功效时,这一点尤其重要。有鉴于此,我们试图生成针对一种细胞表面分子的新型单克隆抗体 (mAb),该分子在不同物种的 MSCs 中高表达。使用 CD106 (VCAM-1) 选择的绵羊 MSCs 作为免疫原,选择产生针对人和绵羊 MSCs 反应性的 mAb 产生杂交瘤。一种这样的杂交瘤,称为 STRO-4,产生了一种 IgG mAb,该 mAb 与 <5% 的人源和羊源骨髓 (BM) 单核细胞反应。作为单一选择试剂,STRO-4 mAb 能够分别将人源和羊源 BM 中的集落形成纤维母细胞 (CFU-F) 富集 16 倍和 8 倍。用 STRO-4 分离的细胞与通过塑料贴壁分离的 MSC 常见标志物反应,包括 CD29、CD44 和 CD166。此外,当在体外诱导培养条件下放置时,STRO-4(+)MSCs 表现出多谱系分化潜能,并能够形成矿化基质、充满脂质的脂肪细胞和能够形成富含糖胺聚糖的基质的软骨细胞。生化分析表明,STRO-4 鉴定了热休克蛋白-90 (Hsp90β) 的β同工型。除了鉴定出一种识别不同物种来源的 MSCs 表达的高度保守表位的抗体试剂外,我们的研究还表明 Hsp90β 在 MSC 生物学中可能发挥作用。